apl. Prof. Dr. Peter Goebell



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial (2020) Staehler M, Panic A, Goebell P, Merling M, Potthoff K, Herrmann E, de Geeter P, et al. Journal article Toward noninvasive follow-up of low-risk bladder cancer – Rationale and concept of the UroFollow trial (2020) Benderska-Söder N, Hovanec J, Pesch B, Goebell P, Roghmann F, Noldus J, Rabinovich J, et al. Journal article, Review article Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany (2019) Goebell P, Mueller L, Gruellich C, Reichert D, Boegemann M, Doerfel S, Von Der Heyde E, et al. Conference contribution Leitlinienadhärenz (2019) Krege S, Goebell P Journal article Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma (2019) Kahlmeyer A, Stoehr C, Hartmann A, Goebell P, Wullich B, Wach S, Taubert H, Erlmeier F Journal article Presurgical assessments (Assessments vor Operationen) (2019) Kahlmeyer A, Goebell P, Wullich B Journal article, Review article Presurgical assessments (2019) Kahlmeyer A, Goebell P, Wullich B Journal article Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer (2019) Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, et al. Journal article Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry (2019) Staehler M, Goebell P, Müller L, Emde TO, Wetzel N, Kruggel L, Jänicke M, Marschner N Journal article Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC): The androgen receptor-independent active agent in the therapeutic sequence Radium-223 zur Therapie des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC): Der androgenrezeptorunabhängige Wirkstoff in der therapeutischen Sequenz (2019) König F, Strauß A, Johannsen M, Mommsen C, Fricke E, Klier J, Mehl S, et al. Journal article